Completed PHASE1 INTERVENTIONAL 2-arm NCT02243683

Safety Study of Immune System Modulator for Autoimmune Diseases

A Randomized, Placebo Controlled, Double Blind, Dose Escalating, Crossover, Safety and Pharmacokinetic Study of AX-024.HCl in Healthy Male Subjects

Sponsor: Artax Biopharma Inc

Conditions Healthy Volunteers

Interventions AX-024.HCl Placebo

Updated 5 times since 2017 Last updated: Oct 13, 2015 Started: Sep 30, 2014 Primary completion: Nov 30, 2014 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy Volunteers, this trial is completed. The trial is conducted by Artax Biopharma Inc and has accumulated 5 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Artax Biopharma Inc
Centro de Biología Molecular Severo Ochoa, Spain (CBMSO)
ORION Clinical Services
Packaging Coordinators Inc
Simbec Research

Data source: Artax Biopharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Merthyr Tydfil, United Kingdom